rs17160153
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_032447.5(FBN3):c.5905+598A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0228 in 152,206 control chromosomes in the GnomAD database, including 235 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.023 ( 235 hom., cov: 33)
Consequence
FBN3
NM_032447.5 intron
NM_032447.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.910
Publications
1 publications found
Genes affected
FBN3 (HGNC:18794): (fibrillin 3) This gene encodes a memebr of the fibrillin protein family. Fibrillins are extracellular matrix molecules that assemble into microfibrils in many connective tissues. This gene is most highly expressed in fetal tissues and its protein product is localized to extracellular microfibrils of developing skeletal elements, skin, lung, kidney, and skeletal muscle. This gene is potentially involved in Weill-Marchesani syndrome. [provided by RefSeq, Mar 2016]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.166 is higher than 0.05.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| FBN3 | ENST00000600128.6 | c.5905+598A>G | intron_variant | Intron 47 of 63 | 1 | NM_032447.5 | ENSP00000470498.1 | |||
| FBN3 | ENST00000270509.6 | c.5905+598A>G | intron_variant | Intron 46 of 62 | 1 | ENSP00000270509.2 | ||||
| FBN3 | ENST00000601739.5 | c.5905+598A>G | intron_variant | Intron 47 of 63 | 1 | ENSP00000472324.1 | ||||
| FBN3 | ENST00000651877.1 | c.6031+598A>G | intron_variant | Intron 47 of 63 | ENSP00000498507.1 |
Frequencies
GnomAD3 genomes AF: 0.0227 AC: 3459AN: 152088Hom.: 232 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
3459
AN:
152088
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.0228 AC: 3470AN: 152206Hom.: 235 Cov.: 33 AF XY: 0.0290 AC XY: 2161AN XY: 74428 show subpopulations
GnomAD4 genome
AF:
AC:
3470
AN:
152206
Hom.:
Cov.:
33
AF XY:
AC XY:
2161
AN XY:
74428
show subpopulations
African (AFR)
AF:
AC:
118
AN:
41538
American (AMR)
AF:
AC:
1013
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
AC:
58
AN:
3468
East Asian (EAS)
AF:
AC:
909
AN:
5176
South Asian (SAS)
AF:
AC:
779
AN:
4824
European-Finnish (FIN)
AF:
AC:
378
AN:
10608
Middle Eastern (MID)
AF:
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
AC:
167
AN:
67988
Other (OTH)
AF:
AC:
46
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
151
303
454
606
757
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
48
96
144
192
240
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
592
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.